Samsung Biologics (207940.KS) reported operating profit of 475.6 billion South Korean won in the second quarter of 2025, up from 434.5 billion won last year. Consolidated revenue rose to 1.290 trillion won from 1.157 trillion won in the previous year.
On a standalone basis, the company reported revenue of 1.014 trillion won and operating profit of 477.0 billion won in the second quarter of 2025.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.